Overview

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Status:
Completed

Trial end date:
2017-05-29

Target enrollment:

Participant gender:

Summary

Phase 1 study to investigate the tolerability and safety of lenvatinib in combination with Everolimus in participants with unresectable advanced or metastatic RCC.

Phase:

Phase 1

Details

Lead Sponsor:

Eisai Co., Ltd.

Treatments:

Everolimus
Lenvatinib
Sirolimus